HYDROS Robotic System (HY1000); HYDROS Handpiece (HH1000); HYDROS TRUS Probe (HU1000)
K251082Procept Biorobotics · cleared 2025-10-10 · product code PZP · General and Plastic Surgery
Premarket evidence — what FDA accepted
source quote (p.6)
“The HYDROS Robotic System, consists of the following nine components: • HYDROS Tower • Touchscreen Interfaces - Monitor that supports the Tower Monitor (Tmon) and Surgeon Monitor (Smon) • HYDROS Software • HYDROS Operating System • Embedded Software • Motorpack • Handpiece Arm • TRUS Probe Arm • Foot Pedal. Optional FirstAssist AI feature available during the PLAN step. FirstAssist AI, Transverse: When the FirstAssist AI toggle button is enabled in the transverse view at the angle and depth step, the software provides the handpiece nozzle position and the prostate capsule boundary.”
source quote (p.10)
“Optional FirstAssist AI feature available during the PLAN step. FirstAssist AI, Transverse: When the FirstAssist AI toggle button is enabled in the transverse view at the angle and depth step, the software provides the handpiece nozzle position and the prostate capsule boundary. FirstAssist AI, Sagittal: When the FirstAssist AI toggle button is enabled at the profile landmark step the software will place the 4 landmarks - treatment start (TS), blader neck (BN), mid-prostate (MP) and treatment end (TE). The surgeon has the option to adjust the landmarks as needed. The subject device has an updated AI model for the same functionality of landmark identification.”
source quote (p.26)
“ISO IEC 29147 First edition 2014-02-15 Information technology - Security techniques - Vulnerability disclosure. IEC 80001-1 Edition 1.0 2010-10 Application of risk management for IT-networks incorporating medical devices - Part 1: Roles, responsibilities and activities. AAMI TIR57:2016 Principles for medical device security - Risk management. ANSI NEMA HN 1-2019 American National Standard Manufacturer Disclosure Statement for Medical Device Security. FDA Guidance Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions. FDA Guidance Cybersecurity for Networked Medical Devices Containing Off-the-Shelf (OTS) Software.”
Validation studies (1)
Bench
sample size not stated
standards: IEC 62366-1:2015/COR1:2016, ANSI/AAMI HE75:2009 (R2018), IEC60601-1-2:2020, IEC TR 60601-4-2, IEC 60601-1:2020, IEC 60601-2-37 Edition 2.1 2015, EC 60601-1-6:2020, IEC 60601-2-18: 2009, IEC 80601-2-77: 2019, AAMI TIR69:2017/(R2020), EN ISO 11135:2014+AMD 1:2019, ISO 10993-7:2008+AMD 1:2019, ISO 11138-1:2017, ISO 11138-2:2017, BS EN 556-1:2001, ISO11737-1:2018+AMD1:2021, ISO 11737-2:2019, ISO 11139:2018, ISO 14937:2009, AAMI TIR 14:2016, AAMI TIR 15:2016, AAMI TIR 16:2017, AAMI TIR 28:2016/(R)2020, ISO 11135 Second edition 2014-07-15, ISO 11737-2 Third edition 2019-12, ISO 10993-1:2018, ISO 10993-4:2017, ISO 10993-5:2009, ISO 10993-9:2019, ISO 10993-10:2021, ISO 10993-11:2017, ISO 10993-12:2021, ISO 10993-13:2010, ISO 10993-14:2001, ISO 10993-15:2019, ISO 10993-18:2020, ISO 10993-23:2021, ISTA 3B:2017, ASTM D4332-22, ASTM D4169-22, ASTM F1886/F1886M-16, ASTM F2096-11 (2019), ISO 11607-1:2019, ISO 11607-2:2019, ASTM F88/F88-2023, ASTM F1980-21, MIL-STD-721C, ISO 15223-1:2021, ISO 20417:2021, ISO 7000:2019, ISO 7010 Third edition 2019-07, ISO 17664-2 First edition 2021-02, IEC/TR 60878 Ed. 4.0 2022-11, ISO 17664-1:2021, ANSI AAMI ST98:2022, AAMI TIR 12:2020, ASTM F3208-20, AAMI TIR 99:2024, ASTM F1089-18, ISO 8600-5:2020, ISO 8600-3:2019, ISO 8600-1:2015, ISO 80369-7:2021, ISO CIE 11664-4, First Edition 2019-06, ISO CIE 11664-6, First Edition 2014-02-01, IEC 61966-2-1:1999-10, IEC 62127-1:2022, IEC 61391-1:2006+AMD1:2017, ISO IEC 29147 First edition 2014-02-15, IEC 80001-1 Edition 1.0 2010-10, AAMI TIR57:2016, ANSI NEMA HN 1-2019
Reported performance (0 observations)
FDA source did not state a quantitative performance metric — non-reporting is itself the signal.
Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.
Predicate network
Postmarket — what happened after clearance
Recalls attributed to this device
Recalling firm matches this device's applicant (PROCEPT BIOROBOTICS CORPORATION) — same firm and product code, not necessarily this device · initiated 2021-07-09
Scope tube tip may detach from the telescoping tube, which is attached to a single-use handpiece, a component of an aquablation robotic system. Both tip detachment and entire tip separation form the handpiece may lead to procedural delay for handpiece exchange. Tip detachment can be seen cystoscopically and tip separation from the handpiece may necessitate tip removal from the bladder or prostate.
recall event 88337 (openFDA)
Recalling firm matches this device's applicant (PROCEPT BIOROBOTICS CORPORATION) — same firm and product code, not necessarily this device · initiated 2019-03-06
Certain lots may develop an internal leak due to a micro-crack in a specific weld joint within the device. When the Robot detects this failure, it immediately renders the device inoperable and notifies the user via an error message, which may cause delay and/or inability to complete the procedure.
recall event 82462 (openFDA)
Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device); a recall is shown as device-attributed only when the recall record itself lists this clearance number. Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.
Reimbursement — how devices like this got paid
Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).
Applicable FDA guidance — what the submission is measured against
FDA guidance documents and guiding principles applicable to 510(k) AI/ML devices in the General and Plastic Surgery panel. A curated reference index, not legal or regulatory advice — each item states its own status, and a draft is never binding.
- Final guidance2026-01Clinical Decision Support Software
Clinical decision support · SaMD (general)
New final guidance issued Jan 2026, superseding the Sept 2022 version; narrows the device-CDS scope. Applies to software that informs clinical management.
- Final guidance2026-01General Wellness: Policy for Low Risk Devices
SaMD (general) · Clinical decision support
Revised final (Jan 2026); now addresses noninvasive products estimating physiologic parameters (SpO2, BP, glucose). Reshapes the device / non-device line for AI wellness features.
- Final guidance2025-09Computer Software Assurance for Production and Quality Management System Software
SaMD (general) · Postmarket
Final (Sept 2025). Covers software used in production/QMS (incl. ML development-pipeline tooling), superseding Section 6 of the 2002 GPSV — not device software functions themselves.
- Final guidance2025-06Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions
Cybersecurity · Software premarket content
Reissued June 2025 (retitled 'Quality Management System', was Sept 2023 'Quality System'); adds coverage of FD&C Act §524B cyber devices.
- Final guidance2024-12Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions
Predetermined Change Control Plan · AI/ML lifecycle · Software premarket content
Final (Dec 2024). Supersedes the April 2023 AI/ML PCCP draft.
- Final guidance2023-10Electronic Submission Template for Medical Device 510(k) Submissions
Software premarket content
eSTAR has been mandatory for 510(k)s since Oct 2023 — operationally unavoidable, though not AI-specific.
- Final guidance2023-08Off-The-Shelf Software Use in Medical Devices
Software premarket content · SaMD (general)
Final (Aug 2023). Applies when a device incorporates off-the-shelf software components (common in ML stacks).
- Final guidance2023-06Content of Premarket Submissions for Device Software Functions
Software premarket content · SaMD (general)
Final (June 2023); replaced the May 2005 'Software Contained in Medical Devices' guidance. Documentation level drives the software content of the submission.
- Final guidance2022-09Policy for Device Software Functions and Mobile Medical Applications
SaMD (general) · Clinical decision support
Current version Sept 2022. Frames which software functions FDA regulates as devices.
- Final guidance2021-10De Novo Classification Process (Evaluation of Automatic Class III Designation)
De Novo pathway
Final (Oct 2021), issued with the De Novo final rule. Most relevant to first-of-a-kind devices without a predicate (DEN-numbered clearances).
- Final guidance2016-12Postmarket Management of Cybersecurity in Medical Devices
Cybersecurity · Postmarket
- Final guidance2002-01General Principles of Software Validation
SaMD (general) · Software premarket content
Still active except Section 6 (superseded Sept 2025 by the Computer Software Assurance final guidance).
- Draft guidance2025-01Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations
AI/ML lifecycle · Software premarket content · Transparency
Draft as of July 2026 (published Jan 2025); finalization is on CDRH's FY2026 agenda but not yet published. Treat as FDA's stated direction, not a binding expectation.
- Draft guidance2024-08Predetermined Change Control Plans for Medical Devices
Predetermined Change Control Plan · Postmarket
Draft (Aug 2024) extending PCCPs beyond AI to all devices under FD&C §515C; not final as of July 2026.
- Guiding principles2024-06Transparency for Machine Learning-Enabled Medical Devices: Guiding Principles
Transparency · AI/ML lifecycle
- Guiding principles2023-10Predetermined Change Control Plans for Machine Learning-Enabled Medical Devices: Guiding Principles
Predetermined Change Control Plan · AI/ML lifecycle
FDA/Health Canada/MHRA joint principles (Oct 2023); companion to the GMLP and Transparency principles.
- Guiding principles2021-10Good Machine Learning Practice for Medical Device Development: Guiding Principles
AI/ML lifecycle · SaMD (general)
FDA/Health Canada/MHRA joint principles (Oct 2021). Foundational, not a binding guidance; IMDRF issued a related GMLP document Jan 2025.
Applicability is derived from the device's FDA advisory panel and pathway — cross-cutting guidances apply to every AI/ML device; panel-specific ones are flagged. Titles, dates, and links verified against fda.gov as of July 2026.